维生素D与甲状腺癌的研究现状  

Current research status of vitamin D and thyroid cancer

作　　者：曾琴[1] 袁晶晶[2] 谢忠建[1] 

机构地区：[1]中南大学湘雅二医院代谢内分泌科,长沙410011 [2]中南大学湘雅三医院代谢内分泌科

出　　处：《中华内分泌代谢杂志》2017年第6期525-528,共4页Chinese Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金面上项目（81471055、81272973、81072219）

摘　　要：维生素D参与体内多种生物学过程，1，25-二羟维生素D[1，25-（OH）2D]是维生素D的活性形式，其经典作用是参与骨骼和钙磷代谢的调节，而其非经典作用则包括调节多种组织细胞的增殖、分化等，其中包括这些组织中肿瘤细胞的增殖和分化。然而1，25-（OH）2D对甲状腺癌细胞的调节作用并不清楚。甲状腺滤泡上皮细胞内有维生素D受体（VDR）的表达，并且还有合成及降解1，25-（OH）2D的酶，在正常滤泡上皮细胞和甲状腺癌细胞中，VDR和这些酶存在差异性表达，提示1，25-（OH）2D和VDR可能有调节甲状腺癌细胞的增殖和分化的功能，如能阐明其调节机制，将为甲状腺癌的防治提供新的靶点。本文主要总结了1，25-（OH）2D在甲状腺癌中的作用机制。Vitamin D participates in a variety of biological processes. 1, 25-dihydroxyvitamin D [ 1,25-（OH）2D] is the active form of vitamin D. Besides its classical role in bone and calcium homeostasis, 1,25-（OH） 2D has many non-classical functions such as regulating proliferation and differentiation of cells in various tissues, including tumor cells as well. However, the role of 1,25- （ OH ） 2 D in thyroid cancer is not clear yet. There are three integral components of the vitamin D pathway in thyroid cells. These components are the vitamin D receptor, 1α-hydroxylase （CYP27BI）, and 24 - hydroxylase （CYP24A1）. Differences in the expression levels of these components in normal thyroid tissue and thyroid cancer tissue may offer clues and lay the foundation for study of the inhibitory function in the pathogenesis of thyroid cancer. This review focuses on the insights gained in the elucidation of the role of 1,25-（OH） 2 D pathway in thyroid cancer, one of the most common endocrine malignancies.

关 键 词：维生素D 甲状腺癌 维生素D受体 

分 类 号：R736.1[医药卫生—肿瘤]